



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61K 47/68 (2017.01)

(21) International Application Number:

PCT/US2021/031598

(22) International Filing Date:

10 May 2021 (10.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/023,495 12 May 2020 (12.05.2020) US
63/180,795 28 April 2021 (28.04.2021) US

(71) Applicant: **MACROGENICS, INC.** [US/US]; 9704 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: **BOHAC, Gerry Chester**; 9704 Medical Center Drive, Rockville, MD 20850 (US). **LOO, Deryk**; 9704 Medical Center Drive, Rockville, MD 20850 (US). **SCRIBNER, Juniper A.**; 9704 Medical Center Drive, Rockville, MD 20850 (US). **WIGGINTON, Jon Marc**; 9704 Medical Center Drive, Rockville, MD 20850 (US).

(74) Agent: **GRANT, Bruce D.** et al.; Grant IP, Inc., 2385 Camino Vida Roble, Suite 102, Carlsbad, CA 92011 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION




Figure 1

(57) Abstract: The present invention is directed to dosing regimens for administering a humanized anti-B7-H3 antibody conjugated to at least one duocarmycin moiety (a "B7-H3-ADC") for the treatment of cancer, particularly a cancer associated with expression of B7-H3. The invention particularly concerns the use of such B7-H3-ADC optionally in combination with a PD-1 binding molecule for the treatment of cancer. The invention particularly concerns the use of such B7-H3-ADC and an anti-PD-1 antibody or a PD-1 X LAG-3 bispecific molecule. The invention is directed to the use of such molecules, and to the use of pharmaceutical compositions and pharmaceutical kits that contain such molecules and that facilitate the use of such dosing regimens in the treatment of cancer.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*